This protocol applies to patients with a confirmed diagnosis of type 1 autoimmune pancreatitis — also known as lymphoplasmacytic sclerosing pancreatitis — as classified by the International Consensus Diagnostic Criteria (ICDC).
The ICDC distinguishes type 1 AIP from type 2 AIP (idiopathic duct-centric pancreatitis, IDCP). Because type 1 and type 2 differ substantially in natural history, diagnostic criteria, and management, this protocol is specific to type 1 AIP and does not apply to IDCP.
Management of confirmed type 1 AIP centres on corticosteroid-based therapy, with several distinct regimens to consider depending on the clinical context. The full protocol details all regimen options, sequencing, and decision criteria — available via the link below.
DOI: 10.1016/j.cgh.2019.04.052
The international consensus diagnostic criteria (ICDC) classify AIP as type 1 AIP or lymphoplasmacytic sclerosing pancreatitis, type 2 AIP or idiopathic duct centric pancreatitis (IDCP), or AIP not otherwise specified.
Because of the significant differences among type 1 and type 2 AIP with regard to natural history, diagnostic criteria, and management, the term AIP is restricted to lymphoplasmacytic sclerosing pancreatitis, whereas type 2 AIP is termed IDCP.
View source ↗